Anti-CD19-Anti-CD3 Bispecific Molecule

Only %1 left

Catalog #

100441

As low as $390 *

Cat # Size Price*

Qty

Bulk/Custom

Add to Favorites

*US Pricing only. For international pricing, please contact your local distributor.

●

Purchase

●

Description

Anti-CD19-Anti-CD3-His-Tag is a purified recombinant human bispecific T cell Engager (BiTE®). This molecule has been tested for specific activity in both ELISA binding assay to CD19-biotin and functional reporter assays using Jurkat/NFAT-luc (BPS Bioscience #60621) or Jurkat/IL2-Luc reporter (BPS Bioscience #60481) cell lines in the presence of CD19+ Raji cells.

●

Synonyms

BiTE®, cd19 BiTE®, bispecific antibody, cd3 BiTE®

●

Product Data Gallery

4-20% SDS-PAGE Coomassie Staining

NFAT Jurkat: Activation of Jurkat Reporter by CD19xCD3 Molecule in Presence of CD19+ Raji Cells

IL-2 Jurkat: Activation of Jurkat Reporter by CD19xCD3 Molecule in Presence of CD19+ Raji Cells

Product Info

Storage and Usage

Citations

Species

Human

Host Species/Expression System

HEK293

Purity

≥90%

Supplied As

Aqueous buffer solution.

Purification

Ni-NTA affinity purification of the His-tag protein from HEK293 cells.

Format

Aqueous buffer solution

Formulation

8 mM phosphate, pH 7.4, 110 mM NaCl, 2.2 mM KCl, and 20% glycerol

54 kDa + glycans

Glycosylation

This protein runs at a higher MW by SDS-PAGE due to glycosylation.

UniProt #

P15391

Background

The use of bispecific antibodies, in formats such as BITE® (bispecific T-cell engager), has been approved for the treatment of diseases such as acute lymphoblastic leukemia (ALL). One example is blinatumomab. Bispecific antibodies can bring to cancer cells via an anti- cancer antigen, such as CD19 (cluster of differentiation 19), and T cells, and induce cytotoxicity against cancer cells. CD19 is considered a nearly ideal target for cancer immunotherapy, as it is expressed at low levels in immature B cells. This immature population is then able to replenish the B cell pool of the body after treatment. CD3 on the other hand is a T cell receptor essential for the activation of T cells. Further studies into anti-CD19-anti-CD3 molecules will deepen our knowledge of their mechanism of actions, and provide further options for cancer treatment.

Storage/Stability

Stable for at least 12 months at -80°C.

Assay Conditions

Functional activity of anti-CD19-anti-CD3 bispecific molecule was measured using Jurkat effector cells with endogenous TCR/CD3 and transfected reporter NFAT-Luc or IL-2 promoter-Luc and incubated with increasing concentrations of a CD19xCD3 bispecific molecule , in the presence or absence of CD19+ Raji cells. The bispecific molecule (BiTE®) simultaneously then binds to TCR/CD3 on the Jurkat reporter cells and tumor antigen CD19 on the target Raji cells. Finally, the bispecific molecule binding stimulates NFAT or IL-2 luciferase activity.

Applications

Anti-CD19-Anti-CD3-His-Tag can be used as a reference BiTE® for studying CD19+ cancer cell-mediated T cell activation, using either primary T cells or reporter cell lines such as the NFAT Jurkat Luciferase Cell Line.

Shipping Temperature

-80°C

Notes

This product is for research use only. It is not suitable for human diagnostic or therapeutic use.

Warnings

Avoid freeze/thaw cycles.

Scientific Category

Immunotherapy, CAR-T

Regulatory Status

Research Use Only

Skip to the end of the images gallery

Skip to the beginning of the images gallery

Anti-CD19-Anti-CD3 Bispecific Molecule

PRODUCTS

SERVICES

RESOURCES

COMPANY